ASTRO Virtual Meeting Center

Log-in / Create Account

Session Information

2008 Annual Meeting

Click here to go to the previous page

Challenging Lung Cancer Cases

Track : EDU

Program Code: EDU306

Date: Tuesday, September 23, 2008

Time: 7:15 AM to 8:45 AM EST

Duration: 4610 Minutes

Location: 210

SPEAKER(S):

Walter Curran, Chairman and Professor, Emory University School of Medicine

Joseph Friedberg, Chief and Associate Professor of Surgery, University of Penn Medical Center

Corey Langer , M.D. , Fox Chase Cancer Center, Philadelphia, PA

Corey J. Langer, MD, is a Professor of Medicine and Director of Thoracic Oncology at the University of Pennsylvania in Philadelphia. He was previously the Medical Director Of Thoracic Oncology at FCCC. A member of the Thoracic, Head and Neck, and Brain Tumor Subcommittees of the Radiation Therapy Oncology Group (RTOG), Dr Langer also serves as Chair of the RTOG Medical Oncology Committee and as Vice-Chair of the group. He is a member of the Thoracic and Head and Neck Core Committees of the Eastern Cooperative Oncology Group and previously chaired the Thoracic Core Committee of the Fox Chase Regional Oncology Group, where he chaired its research committee. In addition, he is an active member of multiple professional and scientific societies, including the American College of Physicians, the American Society of Clinical Oncology, the American Association for Cancer Research, the Society of Head and Neck Surgeons, and the International Association for Study of Lung Cancer, among others. Dr. Langer serves as a reviewer of NCI Protocol Submissions. He is an Associate Editor of Clinical Lung Cancer and serves on the Editorial Board of Clinical Advances in Hematology and Oncology. He is also an editorial reviewer for the Journal of Clinical Oncology, Cancer, and Investigational New Drugs and an advisor and commentator for Oncology Online. His research interests include phase I/II studies of the taxanes, gemcitabine, and topoisomerase I inhibitors; salvage treatment for relapsed lung cancer; concurrent chemotherapy and re-irradiation for relapsed squamous cell carcinoma of the head and neck; and the role of combined modality therapy in the treatment of lung cancer. He also pursues clinical research in thyroid cancer and mesothelioma. Recent publications include articles on concurrent chemotherapy and re-irradiation with paclitaxel and cisplatin in recurrent head and neck cancer as well as phase II and phase III research papers on PS 2 patients with advanced NSCLC. His work has also appeared in the Journal of Clinical Oncology, Cancer, Oncology, and Clinical Cancer Research. Graduating Phi Beta Kappa, Dr Langer received his bachelor�s degree and then his medical degree in 1981 from Boston University. He completed an internship and residency in medicine at the Graduate Hospital of the University of Pennsylvania in 1984 and the first 2 years of fellowship in hematology/oncology at the Presbyterian University of Pennsylvania Medical Center, both in Philadelphia. He completed his fellowship in oncology at Fox Chase Cancer Center in 1987. He is board certified in internal medicine, hematology, and oncology. Dr Langer has been a fellow of the American College of Physicians since 1996. Until he transitioned to the University of Pennsylvania, he was a member of the non-small cell lung cancer and small cell lung cancer guidelines committee of the National Comprehensive Cancer Network from its inception.

Benjamin Movsas, M.D., Henry Ford Hospital, Detroit

Michael J. Simoff, M.D., Henry Ford Medical Center

LEARNER OUTCOMES:

Analyze critical controversies in Stage IIIA NSCLC (e.g., role of surgery)
Discuss the role of adjuvant radiation in node-positive resected NSCLC
Recognize the emerging role of stereotactic body radiation therapy (SBRT) in lung cancer